Atsunori Kaneshige
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Atsunori Kaneshige has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Longchuan Bai
2 shared publications- Adam H. Courtney
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication - Alejandra Rosario-Crespo1 shared publication
- Bo Wen
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, USA
1 shared publication Chang H. Kim
1 shared publicationClaire E. Shudde
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (3)
Cytokine-independent activation of STAT5 promotes the persistence and function of CD4+ regulatory T cells
- 22 July 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (3)
Open AccessCytokine-independent activation of STAT5 promotes the persistence and function of CD4+ regulatory T cells
- 2 February 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (6) , 703-711
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
Signal transducer and activator of transcription 5 (STAT5) is an attractive therapeutic target, but successful targeting of STAT5 has proved to be difficult. Here we report the development of AK-2292 as a first, potent and selective small-molecule degrader of both STAT5A and STAT5B isoforms. AK-2292 induces degradation of STAT5A/B proteins with an outstanding selectivity over all other STAT proteins and more than 6,000 non-STAT proteins, leading to selective inhibition of STAT5 activity in cells. AK-2292 effectively induces STAT5 depletion in normal mouse tissues and human chronic myeloid leukemia (CML) xenograft tissues and achieves tumor regression in two CML xenograft mouse models at well-tolerated dose schedules. AK-2292 is not only a powerful research tool with which to investigate the biology of STAT5 and the therapeutic potential of selective STAT5 protein depletion and inhibition but also a promising lead compound toward ultimate development of a STAT5-targeted therapy.
- 2 February 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (6) , 703-711
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
Signal transducer and activator of transcription 5 (STAT5) is an attractive therapeutic target, but successful targeting of STAT5 has proved to be difficult. Here we report the development of AK-2292 as a first, potent and selective small-molecule degrader of both STAT5A and STAT5B isoforms. AK-2292 induces degradation of STAT5A/B proteins with an outstanding selectivity over all other STAT proteins and more than 6,000 non-STAT proteins, leading to selective inhibition of STAT5 activity in cells. AK-2292 effectively induces STAT5 depletion in normal mouse tissues and human chronic myeloid leukemia (CML) xenograft tissues and achieves tumor regression in two CML xenograft mouse models at well-tolerated dose schedules. AK-2292 is not only a powerful research tool with which to investigate the biology of STAT5 and the therapeutic potential of selective STAT5 protein depletion and inhibition but also a promising lead compound toward ultimate development of a STAT5-targeted therapy.